Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | SPAST | Q9UBP0 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 5/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658660 | 1.00 | ROCK2 (0.46) | ROCK2ROCK1HTTPRKCQPRKCD | |
| SCHEMBL30534249 | 1.00 | ROCK2 (0.46) | ROCK2ROCK1HTTPRKCQPRKCD | |
| SCHEMBL29465145 | 1.00 | ROCK2 (0.46) | ROCK2ROCK1HTTPRKCQPRKCD | |
| SCHEMBL22658659 | 1.00 | ROCK2 (0.46) | ROCK2ROCK1HTTPRKCQPRKCD | |
| SCHEMBL19035699 | 0.85 | PRKCQ (0.49) | ROCK2ROCK1HTTPRKCQPRKCD | |
| SCHEMBL30534242 | 0.82 | ROCK2 (0.42) | ROCK2ROCK1HTTPRKCQPRKCD | |
| SCHEMBL22658607 | 0.78 | HTT (0.46) | ROCK2ROCK1HTTPRKCQPRKCD | |
| SCHEMBL22658606 | 0.78 | HTT (0.46) | ROCK2ROCK1HTTPRKCQPRKCD | |
| SCHEMBL82195 | 0.77 | HTT (0.49) | ROCK2ROCK1HTTPRKCQPRKCD | |
| SCHEMBL4779990 | 0.76 | PRKCQ (0.53) | ROCK2ROCK1PRKCQPRKCDNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234942-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234942-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, CLN6 | ROCK2 3864/4885ROCK1 3949/4885HTT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.